Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

By sjmartinez • March 13, 2025

Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, Wander SA, Bardia A, Ko N, Moy B, Ellisen LW, Isakoff SJ. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025 Mar 11;11(1):27. doi: 10.1038/s41523-025-00741-y. PMID: 40069204.

Tags: Hematology/Oncology, Publications

Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer

Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Patient, care partner,[...]

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]